Long non-coding RNAs in cutaneous biology and keratinocyte carcinomas

Long non-coding RNAs (lncRNAs) are a largely uncharacterized group of non-coding RNAs with diverse regulatory roles in various biological processes. Recent observations have elucidated the functional roles of lncRNAs in cutaneous biology, e.g. in proliferation and differentiation of epidermal keratinocytes and in cutaneous wound repair. Furthermore, the role of lncRNAs in keratinocyte-derived skin cancers is emerging, especially in cutaneous squamous cell carcinoma (cSCC), which presents a significant burden to health care services worldwide and causes high mortality as metastatic disease. Elucidation of the functions of keratinocyte-specific lncRNAs will improve understanding of the molecular pathogenesis of epidermal disorders and skin cancers and can be exploited in development of new diagnostic and therapeutic applications for keratinocyte carcinomas. In this review, we summarize the current evidence of functionally important lncRNAs in cutaneous biology and in keratinocyte carcinomas.


Introduction
Skin cancers are the most common cancer types globally with increasing incidence [1,2]. Melanoma, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC) are the three major types of skin cancer. Cumulative exposure to ultraviolet radiation (UVR) is a common risk factor for skin cancers, but they differ with respect to mutational profiles and alterations in cellular signaling pathways [3]. Melanoma originates from melanocytes, whereas BCC and cSCC originate from epidermal keratinocytes and are, therefore, called keratinocyte carcinomas (KC). The best preventive measure against skin cancer is avoiding excessive and cumulative exposure to sunlight and other sources of UVR. In addition, early detection and treatment is pivotal for the prognosis of the disease. The mortality rates for skin cancers vary between populations. However, taking into account the considerably higher incidence of KC over melanoma, it is estimated that the global mortality rate for all non-melanoma skin cancers (NMSCs) including BCC and cSCC, is even higher than for melanoma [4].
A significant proportion of human genome encodes noncoding RNAs (ncRNAs), including ribosomal RNA (rRNA) and transfer RNA (tRNA), and other functionally relevant ncRNAs, roughly categorized to small (sncRNAs) and long non-coding RNAs (lncRNAs) [5]. MicroRNAs (miRNAs) present an evolutionary conserved subgroup of sncRNAs deregulated in different cancers, including BCC and cSCC [6,7]. LncRNAs are single-stranded RNA molecules larger than 200 nucleotides in size, lacking protein-coding capacity and sequence conservation [8]. It has become increasingly evident that they regulate a variety of cellular functions, and that aberrant expression of lncRNAs plays a role in various pathological conditions including cancer [9].
The mutational background for cSCC and BCC is well documented, and several driver mutations in protein coding genes have been identified [10][11][12][13][14][15][16][17]. These same driver gene mutations are also found frequently in epidermal keratinocytes in normal sun-exposed skin [18], indicating, that also other factors, e.g. changes in non-coding genes and the microenvironment, are also necessary for development of cSCC [19]. Mutations in the non-coding regions of genome can affect chromatin structure, transcription factor binding, and gene expression [20]. Moreover, these mutations may alter expression or secondary structure of lncRNAs or interfere with lncRNA interaction with other regulatory factors [21]. The consequence of non-coding mutations in lncRNA expression and function in cutaneous carcinogenesis and skin cancer development is largely unknown. However, recent evidence suggests that lncRNAs participate in the complex cancer signaling network in skin malignancies. Elucidation of their role in cutaneous biology is likely to reveal new molecular targets for diagnostics and therapeutic intervention. In this review, we summarize the current findings of the function of lncRNAs in cutaneous biology and in keratinocyte carcinomas.

Keratinocyte carcinomas
Keratinocyte carcinomas BCC and cSCC are the most common forms of skin cancer with increasing incidence globally [22,23]. The primary cause for KCs is chronic exposure to UVR, and other important risk factors include immunosuppression, human papillomavirus infection, and chronic cutaneous ulceration [22][23][24]. While BCC is the most common human malignancy, cSCC accounts for the majority of deaths among KCs [25,26]. In addition, a personal history of KCs is associated with a risk for other cancers [27]. In contrast to BCC, which rarely metastasizes, the risk of metastasis for cSCC is estimated as 1-4% and the prognosis of metastatic cSCC is poor [26]. Overall, the high prevalence of KCs poses a marked burden on health care worldwide and has a major impact on the patients' quality of life [28].
Development of KC involves accumulation of several molecular and cellular changes. Both BCC and cSCC harbor a substantial mutational burden, mainly due to cumulative UV exposure typically observed as C → T transitions in the DNA [12][13][14][15][16][17][18][19]. Several studies using BCC and cSCC murine models suggest that these cancers arise from multiple cellular origins, e.g. from different stem cell populations in the basal layer of the epidermis, hair follicle bulge or sebaceous gland [29].
Actinic keratoses (AKs) are early precursors of cSCC and Bowen's disease is in situ cSCC (cSCCIS), where atypical keratinocytes extend throughout the epidermis [35]. If left untreated, these lesions develop to invasive cSCCs. In general, patients with BCCs or resectable primary cSCCs have a good prognosis, whereas metastatic cSCC is associated with poor outcome [26]. Radiation and chemotherapy can be used for advanced and recurrent high-risk tumors that cannot be excised, especially those located in the facial area [36]. Recently, targeted therapies have been approved for therapy of advanced BCC and cSCC. Vismodegib, an inhibitor of Hedgehog pathway, is available for treatment of locally advanced BCC [37]. Immune checkpoint inhibitor, programmed cell death protein-1 (PD-1) blocking monoclonal antibody cemiplimab, has been approved for treatment of patients with locally advanced or metastatic cSCC [38]. Nevertheless, there is an urgent need for additional targeted therapies for advanced cSCCs and for prognostic biomarkers for predicting the risk of recurrence and metastatic potential of cSCC.

Long non-coding RNAs
Long non-coding RNAs (lncRNAs) are single-stranded RNAs mainly transcribed by RNA polymerase II, which undergo post-transcriptional processing, such as 5′-capping, splicing and polyadenylation [8]. This way lncRNAs closely resemble messenger RNAs (mRNA), but they are not translated to proteins. Some lncRNAs are rapidly degraded after transcription, whereas others are extremely stable [39,40]. A rapid turnover of lncRNAs enables a dynamic cellular response via specifically induced lncRNAs, for instance in DNA damage, immune response, and cellular differentiation [41][42][43].
LncRNAs are poorly conserved between species [44][45][46]. In general, lncRNAs are considered larger than 200 nucleotides in size. This division, however, is not strict, as some lncRNAs are less than 200 nucleotides in size, and some lncRNAs can function both as regulatory lncRNAs and can be processed to sncRNAs [47]. Classification of lncRNAs into distinct subgroups is commonly based on their genomic location.
Long intergenic or intervening non-coding RNAs (lin-cRNAs) are transcribed from distinct loci, often from their own promoters, whereas intronic lncRNAs are transcribed from intronic regions within protein-coding gene [45,47]. Sense lncRNAs are transcribed from the sense strand also containing exons of protein-coding genes [47]. Natural antisense transcripts (NATs) are transcribed from the antisense strand of a protein-coding gene, overlapping either exonic or intronic regions [47]. Bidirectional lncRNAs are produced divergently from the same promoter of a proteincoding gene. Circular RNAs (circRNA) are a recently discovered group of lncRNAs structurally different from most lncRNAs. They are produced by back splicing of precursor mRNAs or lncRNAs, resulting in covalently closed circular RNAs without polyadenylation, and they can originate from intronic or exonic transcripts [48].
LncRNAs are specifically expressed during normal physiological processes including cell differentiation and tissue development, whereas untimely and aberrant expression of lncRNAs in various pathological conditions is becoming evident [9][10][11]. Thus, alternative classification has been suggested, for instance by grouping them into lncRNAs regulating gene expression locally (cis) or in distance (trans) [49], or by other criteria such as subcellular localization, association with DNA-elements, or functional mechanism [50].

Molecular functions of lncRNAs
In general, the regulatory role of lncRNAs is based on binding to specific effector molecules by sequence complementarity or structural recognition to mediate gene expression. The single-stranded structure of lncRNAs and folding into unique secondary and tertiary structures gives them the ability to bind to RNA, DNA or proteins and this way control diverse cellular functions [8,51,52] (Fig. 1). LncRNAs typically exhibit a strict cell and tissue-specific expression and subcellular localization, indicating strictly controlled regulatory role for distinct lncRNAs [44,53]. Specific localization of distinct lncRNAs to cytoplasm, nucleus, or other cellular compartments is likely to reflect their function ( Fig. 1). In addition, some lncRNAs are secreted in extracellular vesicles and exosomes, and can exert their effect in adjacent cells and in cells in other tissues [54,55]. In general, lncRNA mechanism of action can be divided into four main types: signals, guides, decoys, and scaffolds [51]. Simply, they can also be classified as nuclear lncRNAs in mediating gene transcription [56] or cytoplasmic lncRNAs controlling post-transcriptional events and mRNA stability [57] (Fig. 1).

Regulation of epidermal differentiation by lncRNAs
The skin serves as a protective barrier against several environmental threats, including microbes, chemicals, and physical insults, and it also controls water loss and thermoregulation. Skin consists of several different cell types and stem cell populations, which co-operate to maintain and regenerate its structure and function [58]. The epidermal layer of skin is under continuous turnover, as the cells generated from the basal keratinocytes lose their proliferative capacity, commit to terminal differentiation, and move towards skin surface [59]. During this process, keratinocytes undergo major morphological and mechanical changes due to spatiotemporal alteration in their transcriptional program [60]. Several markers for keratinocyte differentiation have been identified and the chromatin dynamics play a crucial role during this process [61][62][63].
Transcriptional changes during differentiation of epidermal keratinocytes also involve alterations in the expression of non-coding RNAs and accordingly specific lncRNAs have been implicated in keratinocyte differentiation [64,65] (Fig. 2). Differentiation antagonizing non-protein coding RNA (DANCR) is downregulated during terminal differentiation of keratinocytes and it is required for maintaining the undifferentiated phenotype of epidermal progenitor cells [66]. DANCR is a negative regulator of MAF and MAFB transcription factors, which are important regulators of differentiation in various cell types [67]. DANCR represses the expression of MAF and MAFB epigenetically by guiding a chromatin-modifying protein complex to the promoters of their genes [66]. In contrast to DANCR, terminal differentiation-induced ncRNA (TINCR) is highly expressed in differentiating keratinocytes specifically in the suprabasal layers of human epidermis [68]. TINCR promotes keratinocyte differentiation by stabilizing mRNAs coding for proteins involved in keratinocyte differentiation e.g. transcription factors MAF and MAFB, together with an RNA-binding protein STAU1 [68]. Together, DANCR and TINCR are able to regulate the expression of a broad range of genes in keratinocytes and this way function as pivotal regulators of epidermal differentiation.
The expression of LINC00941 is downregulated upon keratinocyte differentiation, and it antagonizes the function of small proline rich protein 5 (SPRR5), which promotes differentiation of keratinocytes [69]. The expression of beta1-adjacent long non-coding RNA (BLNCR) is also downregulated during keratinocyte differentiation, preceding downregulation of ITGB1, which codes for integrin β1, an epidermal stem cell marker adjacent to BLNCR gene [70,71]. BLNCR and ITGB1 are both transcriptionally regulated by transcription factors p63 and AP-1, and loss of BLNCR and ITGB1 expression may be an early event resulting in loss of proliferative capacity of keratinocytes and in subsequent terminal differentiation [71].
Progenitor renewal associated non-coding RNA, (PRANCR), is one of the most recently characterized lncR-NAs involved in epidermal homeostasis [72]. Depletion of PRANCR leads to reduced proliferative capacity and differentiation of keratinocytes. PRANCR regulates the Fig. 1 Molecular functions of lncRNAs. Nuclear lncRNAs can regulate epigenetic changes by a decoying or b guiding chromatin-modifying complexes to specific genomic loci. c lncRNAs can induce chromosomal looping to control gene expression by simultaneously binding to protein complexes or specific DNA elements. LncRNAs can inhibit gene transcription d by blocking a transcription factor binding site or f by binding to RNA polymerase. g LncRNAs may contribute to transcriptional activation by guiding transcription factors or other co-factors to gene promoters. e LncRNAs can regulate alternative splicing that can occur by lncRNA binding to mRNA and blocking the splice-site. LncRNAs can also recruit and guide splicing factors to the sites of transcription. Cytoplasmic lncRNAs can regulate mRNA stability h directly by binding to mRNAs or i indirectly by sequestering miRNAs by complementary base pairing. j Some lncRNAs can be secreted to extracellular vesicles or exosomes allowing them to mediate intercellular signaling. k LncRNAs can serve as scaffolds to promote the assembly of active ribonucleoprotein complexes in the cytoplasm or nucleus. l LncRNAs can aid intracellular translocation of proteins expression of several genes coding for cell cycle regulators, including E2F transcription factor target genes [72]. In addition, H19 imprinted maternally expressed transcript (H19) and SCC misregulated transcript-2 (SMRT-2) are recently identified lncRNAs induced during differentiation of epidermal keratinocytes [73,74]. Depletion of SMRT-2 results in repression of several genes associated with epidermal differentiation and development [74]. These genes are also regulated by zinc finger protein 750 (ZNF750) and Kruppel like factor 4 (KLF4), suggesting that SMRT-2 functions upstream of the ZNF750-KLF4-axis [74]. ZNF750 functions downstream of p63 in driving epidermal differentiation by upregulating KLF4 [75]. Moreover, ZNF750 upregulates expression of lncRNA TINCR [76]. Taken together, these observations provide a regulatory link between SMRT-2, ZNF750 and TINCR in regulation of epidermal keratinocyte differentiation.
As aberrant keratinocyte differentiation and stem-cell characteristics are involved in KC tumor development [77,78], it is not surprising that the expression of keratinocyte differentiation inducing lncRNAs, SMRT-2 and TINCR, are strongly downregulated in cSCC [66,74,79]. Many of the lncRNAs associated with epidermal differentiation listed here are not implicated in cSCC and it will be important to investigate their mechanistic role in progression of cutaneous cancers.

LncRNAs in cutaneous wound repair
Cutaneous wound repair is a complex and strictly controlled process, which involves co-operation of several different cell types, including keratinocytes, fibroblasts, endothelial cells, and inflammatory cells [80]. Delayed wound healing resulting in chronic ulcers is usually associated with an underlying condition, such as insufficient arterial or venous circulation, diabetes or prolonged inflammation [80]. Chronic wounds also carry a risk of developing to cSCC [81].
The role of lncRNAs in normal wound repair or in pathogenesis of chronic ulcers is largely unknown. LncRNA expression profile in Marjolin ulcer, a rare, aggressive type of cSCC that evolves in scars or chronic wounds has been reported, but functional characterization of the lncRNAs in this condition is lacking [82]. Growth arrest-specific 5 lncRNA (GAS5) is a repressor of glucocorticoid receptor expression, which serves as a tumor suppressor in many cancers [83]. GAS5 has been shown to promote wound healing by inducing epithelialization and angiogenesis via c-myc inhibition [84]. Metastasis associated lung adenocarcinoma and SMRT-2 promote and DANCR, BLNCR, and LINC00941 inhibit keratinocyte differentiation. Deregulation of lncRNAs is becoming evident in cSCC progression. The expression of TINCR, SMRT-2, and LINC00520 is downregulated and the expression of PICSAR, PREC-SIT, MALAT1, AK144841, LINC00319, and LINC01048 is upregulated in cSCC. These lncRNAs could be used as new prognostic markers and as novel therapeutic targets in cSCC transcript 1 (MALAT1), a tumor-promoting lncRNA in many cancers [85] has been shown to stimulate repair of ischemic wounds by promoting migration of human dermal fibroblasts through hypoxia-inducible factor-1α (HIF-1α) signaling [86,87]. In addition, lncRNA H19 has been shown to promote wound healing via HIF-1α pathway [88,89].
Wound and keratinocyte migration-associated lncRNA 1 and 2 (WAKMAR1 and WAKMAR2) are two recently identified lncRNAs, which play an important role in cutaneous wound repair [90,91]. Expression of WAKMAR1 is highly upregulated in keratinocytes during wound repair and its expression stimulates keratinocyte migration and wound re-epithelization [90]. Expression of both WAKMAR1 and WAKMAR2 is induced by TGF-β and downregulation of their expression inhibits migration of keratinocytes, resulting in delayed wound re-epithelization [90,91]. Accordingly, the expression of both WAKMAR1 and WAKMAR2 is reduced in keratinocytes in the edge of chronic wounds in vivo [90,91]. Moreover, upregulation of WAKMAR2 expression inhibits production of inflammatory chemokines by keratinocytes, and this way promotes wound healing [91]. WAKMAR1 exerts its function by sequestering DNA methyltransferases, resulting in upregulation of the expression of E2F1 transcription factor and subsequent regulation of the expression of its target genes [90].

Regulation of lncRNAs by UVR
Exposure of skin to UVR induces several cellular responses. Activation of the inflammatory response manifesting as erythema in skin is an acute response after UV exposure [92]. UVR induces DNA damage in epidermal keratinocytes, which triggers a stress response, activation of p53 and DNA repair [93]. UV-induced DNA damage leads to systemic immunosuppression [94][95][96] which is exploited in treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis [97].
UVR leads to altered lncRNA expression in epidermal keratinocytes [98], melanocytes, [99] and dermal fibroblasts in culture [100][101][102][103]. The biological response of skin to UVA and UVB is distinct due to their different penetration to the skin and they trigger distinct expression pattern of lncRNAs in HDFs [101]. It is possible, that some of these lncRNAs play a role in the early cellular stress response or acute inflammation following exposure to UV. Also, several UV-regulated lncRNAs in keratinocytes show a similar expression trend in cSCC and BCC, suggesting a role for them in epidermal carcinogenesis [98].
A subset of UV-induced lncRNAs has been functionally characterized [102][103][104][105]. In keratinocytes, the expression of lincRNA-p21 is markedly induced by UVB through a p53-dependent mechanism and it exerts a tumor suppressive role by triggering UVB-induced apoptosis and cell cycle arrest [105]. Accordingly, a tumor suppressive function for lincRNA-p21 has been reported in head and neck SCC [106]. Psoriasis susceptibility-related RNA gene induced by stress (PRINS) is a lncRNA induced by UVB and other stress signals, such as serum starvation or translational inhibition in HaCaT cells, an epidermal keratinocyte derived cell line, which lacks functional p53 [104]. Elevated expression of PRINS in psoriatic epidermis has also been reported, suggesting a role for PRINS in pathogenesis of psoriasis [104].
Vitamin D is photochemically synthesized in the skin by UVB and recent findings support a cancer protecting role for vitamin D [107]. Interestingly, keratinocytes lacking vitamin D receptor show a distinct lncRNA expression pattern with increased expression of oncogenic lncRNAs and decreased expression of tumor-suppressive lncRNAs, including lin-cRNA-p21 [108]. It appears, that UVR plays a dual role in skin by inducing the innate immune response, but predisposing to systemic immunosuppression and genomic mutations [1,92,97]. It is not known, what is the feasible level of UV exposure and to what extent lncRNAs can mediate the balance between skin homeostasis and carcinogenesis.

LncRNAs in keratinocyte carcinomas
The UV-induced alteration of lncRNA expression in epidermal cells suggests that some of these lncRNAs exert a protective role against carcinogenesis by triggering UVinduced early stress response [98][99][100][101][102][103][104][105] (Table 1). On the other hand, some of them may play a role at the early stage of epidermal carcinogenesis and loss of some differentiationassociated lncRNAs may serve as markers for tumor initiation. In keratinocyte carcinomas, particularly in cSCCs, several lncRNAs are differentially expressed as compared to normal skin or keratinocytes, suggesting a role for them in cSCC progression [109,110]. Some of the deregulated lncR-NAs may function in signaling pathways, which are already mutationally activated or suppressed in cSCC. On the other hand, it is likely that some of these lncRNAs are targeted by UV-induced mutations or by genomic alterations within the lncRNA gene itself, as has been observed in several cancer cell lines [111,112]. As none of the BCC-associated lncR-NAs have been functionally characterized so far, we will focus on lncRNAs implicated in cSCC (Table 1).
Aberrant activation of the ERK1/2 MAPK pathway is one of the central drivers in the molecular pathogenesis of cSCC [113][114][115]. ERK1/2 pathway is activated by UVA radiation [116]. Moreover, mutational activation of epidermal growth factor receptor (EGFR) results in sustained activation of the RAS-RAF-MEK-ERK signaling pathway and promotes cutaneous carcinogenesis [117].

PICSAR plays a tumorigenic role in cSCC
p38-inhibited cutaneous squamous cell carcinoma-associated lincRNA (PICSAR) represents the earliest evidence of a functionally characterized lncRNA in cSCC [110]. The expression of PICSAR is upregulated in cSCC tumor cells in culture and in vivo compared to normal human epidermal keratinocytes (NHEKs) and normal skin [110]. Elevated expression of PICSAR was also noted in vivo in actinic keratosis and cSCC in situ, suggesting a role for PICSAR at the early stage of epidermal carcinogenesis [110]. Silencing of PICSAR expression potently suppresses growth of human cSCC xenografts [110]. Interestingly, PICSAR serves as a regulatory link between p38 and ERK1/2 mitogen-activated protein kinase (MAPK) pathways (Fig. 3a). Inhibition of p38 activity induces PICSAR expression and PICSAR promotes cSCC cell proliferation by promoting ERK1/2 activity via downregulation of dual specificity phosphatase DUSP6 [110]. In addition, PICSAR potently regulates cell adhesion and migration by regulating integrin expression [118], and may this way contribute to cSCC progression and invasion (Fig. 3a).

MALAT1 and LINC00520 play opposite roles in cSCC
MALAT1 is a lncRNA, which has been reported to be deregulated in different types of cancer [85]. Elevated expression of MALAT1 was recently reported in cSCC tumors and it was shown that the expression in cSCC cells is induced by UVB [119]. MALAT1 promotes proliferation, migration, and invasion of cSCC cells and growth of cSCC tumors in vivo and suppresses apoptosis of cSCC cells [119].

3
Mechanistically, MALAT1 interacts with c-Myc to activate transcription of kinectin 1 (KTN1) gene, which is one of the top downregulated genes after MALAT1 depletion. Knockdown of MALAT1 also results in decreased level of EGFR protein, but not EGFR mRNA [119]. These results suggest that MALAT1 contributes to cSCC pathogenesis by upregulating EGFR protein levels via c-Myc and KTN1 [119]. Marked expression of lncRNA AK144841 has been noted in chemically (DMBA/TPA) induced mouse cSCCs compared to healthy skin [79]. The histology and the genomic background of these tumors are very similar to human cSCCs [120]. Sustained activation of HRAS, which is caused by highly carcinogenic DMBA, results in marked induction of EGFR and its ligands in cSCC mouse model [121,122]. In this regard, induction of AK144841 in murine cSCC may be related to EGFR activation. A potential human ortholog with homology to AK144841 has been shown to be expressed at high level in cSCC cell lines compared to NHEKs suggesting, that it may be involved in human cSCC progression [79].
Downregulation of LINC00520 has been noted in A431 cSCC cell line, compared to NHEKs, and overexpression of LINC00520 in A431 cells results in suppression of tumor growth and lymph node metastasis [123]. A431 cells express high levels of EGFR [124]. Reduced expression of EGFR and its downstream targets, PI3K, AKT, VEGF, MMP-2, and MMP-9 was noted in A431 cells overexpressing LINC00520, whereas an opposite effect was noted after LINC00520 depletion [123]. Altogether, these results suggest that LINC00520 plays a tumor suppressive role in cSCC by targeting EGFR [123].

TINCR and SMRT-2 are potential tumor suppressors in cSCC
Poor differentiation of cSCC is associated with risk for metastasis and poor prognosis [77,78]. TINCR and SMRT-2 both promote differentiation of keratinocytes and may this way serve in a protective role in keratinocyte carcinogenesis [68,74]. Accordingly, decreased expression of TINCR and SMRT-2 has been noted in human cSCCs [68,74], and a notable decrease in TINCR expression has been reported in DMBA/TPA-induced murine cSCC tumors compared to normal skin [79]. In addition, marked suppression of SMRT-2 expression has been noted in Rasdriven human organotypic epidermal neoplasia [74]. Together, these two lncRNAs may function as potential tumor suppressors in cSCC. In this context, it is interesting that ZNF750 which upregulates the expression of TINCR in keratinocytes, was recently shown to exert a tumorsuppressive role in SCCs of head and neck, lung, cervix, and skin [76].

LINC01048 and Hippo pathway in keratinocyte carcinoma
Hippo pathway is a well-conserved signaling pathway, which is important in skin development, cutaneous homeostasis and tissue regeneration, and aberrant Hippo signaling has been noted in non-melanoma skin cancers [125]. Recently, upregulation of a previously unknown lncRNA, LINC01048, was reported in cSCC associated with lower overall survival of cSCC patients [126]. LINC01048 promotes cSCC cell growth via the Hippo pathway [126]. Depletion of LINC01048 regulates the levels of the downstream effectors of the Hippo signaling, including yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ). Mechanistically, LINC01048 interacts with transcription factor TAF15 to promote transcription of YAP1 gene [126]. Accordingly, YAP1 and TAZ function as oncogenes in many cancers, including BCC and cSCC [127,128]. Together these results provide interesting new evidence for the role of LINC01048/TAF15/YAP1-axis in cSCC progression.
LINC00319 is a recently identified lncRNA with elevated expression in cSCC shown to correlate with larger tumor size and lymphovascular invasion of cSCC [130]. LINC00319 promotes cSCC cell migration and invasion, and upregulates expression of MMP-2, MMP-9, and markers for epithelial-mesenchymal transition, E-cadherin, and vimentin [130]. PRECSIT regulates the invasion of cSCC cells specifically without affecting cell growth [129], whereas LINC00319 has an anti-apoptotic function and promotes cSCC cell proliferation via miRNA-mediated mechanism [130].

Concluding remarks
The role of lncRNAs in epidermal biology is slowly emerging. The recent findings summarized here elucidate the functional role of lncRNAs in physiological conditions and keratinocyte cancer development, specifically in cSCC (Fig. 2, Table 1). It is noteworthy, that none of the BCCassociated lncRNAs have been functionally characterized yet. Moreover, considering UVR as a common nominator for the development of cSCC and BCC, it remains unclear whether they share the same UV-regulated lncRNAs. These cancers have distinct mutational background and different oncogenic signaling pathways. Therefore, it is likely that there are also specific lncRNAs which, by function, are associated with either cSCC or BCC development by cooperating with various signaling molecules to mediate the expression of tumor promoting or tumor suppressing genes. LncRNAs present great potential in developing new diagnostic and therapeutic approaches. Along with conventional molecular markers, distinct lncRNA expression signature may provide better diagnostic accuracy of the disease. Moreover, therapeutic targeting of tumorigenic lncRNAs may enhance the efficacy of cancer therapy. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.